Not sure where to start? Try searching for your diagnosis above or visit the "Conditions" section.
4 items
A Phase II multicenter trial published in The New England Journal of Medicine found that tulisokibart, a novel monoclonal antibody targeting...
View — ARTEMIS-UC Phase II Trial: Tulisokibart (Anti-TL1A) Achieves Clinical Remission in Moderate to Severe Ulcerative Colitis »Abivax's oral pill obefazimod helped more than a third of ulcerative colitis patients who hadn't responded to initial treatment reach remiss...
View — A Gut Drug Pulls Refractory Ulcerative Colitis Patients Back Into Remission »Merck's tulisokibart became the first anti-TL1A antibody to succeed in a phase 3 trial, helping ulcerative colitis patients reach clinical r...
View — First Anti-TL1A Drug Hits Its Mark in Ulcerative Colitis »Abivax's oral pill obefazimod helped more than a third of ulcerative colitis patients who failed initial treatment reach clinical remission...
View — Oral Drug Helps Hard-to-Treat Ulcerative Colitis Patients Reach Remission »